Podcasts > Archived Podcasts > Industry Focus
This show is no longer producing new episodes. Check out our other shows.
Industry Focus
Healthcare: Biogen's Alzheimer's Drug Goes From Bust To Boon, Plus Why Walgreen's Shuttering 200 Healthcare Clinics
Oct 30, 2019 (24:46)
Biogen's drug pipeline took a massive hit earlier this year when it stopped development of its Alzheimer's disease drug, aducanumab, for a lack of efficacy. Now, Biogen says new data shows it may work after all. Can this drug pass muster with regulators? Also, Walgreen's is closing retail clinics within its stores, but that doesn't mean it's giving up on plans to offer more healthcare services entirely.
- https://www.fool.com/podcasts/?utm_source=podcasts&utm_medium=podcasts&utm_campaign=industryfocus" rel="noopener" target="_blank">TMF's podcast portal
- https://www.youtube.com/user/TheMotleyFool" rel="noopener" target="_blank">YouTube
- https://twitter.com/mfindustryfocus?lang=en" rel="noopener" target="_blank">Twitter
- https://m.facebook.com/groups/217114601988296">Join Our Motley Fool Podcast Facebook Group
- https://www.linkedin.com/company/the-motley-fool">LinkedIn
- https://www.fool.com/ecap/the_motley_fool/stock-up/?aid=9205&source=isusitsz0000002&ftm_cam=stockup&ftm_veh=sidebarhelp&ftm_mes=signup"> StockUp, The Motley Fool's weekly email newsletter
To get 50% off our Stock Advisor service, go to http://if.fool.com/">http://IF.Fool.com.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.